ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.

Cancer Res Commun · 2022 · PMC10010325 · PMID 36922936

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an obvious trendno p-value reported

We also attempted to characterize how CD16A polymorphism impacts ADCC activity with ZL-1211 treatment but did not observe an obvious trend regarding the presence of polymorphisms ( Fig. 2E ).

also in 1,006 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.